Delivery Order SPE2DB22D2211-SPE2DB25FSFEF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units, valued at $2,947.88. This competitive award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, utilizes firm fixed pricing under a non-set-aside procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $1,232.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units. The contract, which is not set-aside, has an ultimate completion date of May 19, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle that...
- The Defense Logistics Agency awarded a delivery order valued at $3,059.76 to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a 60-count package. This non-set-aside, firm fixed-price delivery order was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used to treat atrial fibrillation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $16.2K to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units. The contract is a firm fixed price delivery order with an ultimate completion date of September 8, 2025, and represents a non-set-aside competitive award. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Multaq (dronedarone) 400 mg tablets in quantities of 60 units. This firm fixed-price delivery order has a ceiling value of $19,914.33 and an ultimate completion date of September 11, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Multaq is an...
- The Defense Logistics Agency awarded a $1,871.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a 60-tablet configuration, valued at $22,136.80. This firm fixed-price delivery order, awarded on May 14, 2025, with an ultimate completion date of May 15, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed this work at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,060.55 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price, competitively awarded delivery order was issued on September 15, 2025, with an ultimate completion date of September 16, 2025. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $11,457.08 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on September 9, 2025, with a completion date of September 10, 2025. This competitive award with firm fixed pricing represents a pharmaceutical supply delivery under a child contract arrangement. Multaq (dronedarone) is an antiarrhythmic medication used to treat atrial fibrillation, reflecting the company's role as a critical pharmaceutical supplier for federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,550.46 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Multaq (dronedarone) is an antiarrhythmic medication used in the...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSFEFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units, valued at $4,506.52. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at $1 billion through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a broad range of medications and medical supplies to support military and veteran healthcare systems. Multaq is an antiarrhythmic medication used in cardiac care, reflecting the company's role in providing specialty pharmaceuticals across multiple therapeutic domains to the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 9/17/25 |